PINNACLE India Quality Improvement Program (PIQIP) is India's first outpatient cardiovascular registry established by the American College of Cardiology (ACC) for performance measurement of coronary artery disease (CAD), heart failure (HF), and atrial fibrillation (AF).[@bib0005] Not all sites that contribute data in the PIQIP registry have electronic health record (EHRs)-facilitated documentation capabilities for data collection and entry. There is a push toward implementation of EHRs in federally-funded hospitals in India under the policies initiated by the Indian government.[@bib0010] The evidence-base supporting this policy change is lacking.[@bib0015] This study evaluated the impact of EHRs on documentation of guideline-directed medical therapy (GDMT) in CAD, HF, and AF in India.

Data on GDMT use was collected on patients seeking care among 17 participating cardiology practices in PIQIP between 2011 and 2016. Diagnoses of CAD, HF, and AF were determined based on physicians\' documentation on the OPD card.[@bib0005] The HF cohort comprised of patients with a documented left ventricular ejection fraction ≤40%. GDMT for patients with CAD included prescription of aspirin, clopidogrel, beta-blockers, and angiotensin-converting enzyme inhibitors (ACE-i) or angiotensin receptor blockers (ARBs). For HF patients, GDMT included prescription of beta-blockers, ACE-i or ARBs, and the combination of beta-blockers + ACE-i or ARBs. GDMT for AF included warfarin use. Data on GDMT for each condition represents use of medications by unique patients at any encounter during the study interval. We first assessed differences in baseline characteristics between patients seeking care in EHR versus non-EHR practices. Individual medication prescription for each of the disease states was compared between EHR and non-EHR practices. We then performed logistic regression analyses adjusting for patient's age, sex, practice location (urban vs. rural), history of hypertension or diabetes mellitus, and number of outpatient visits during the study interval to determine whether presence of EHR was independently associated with better documentation of quality. Data integrity was ensured by randomly sampling 25% OPD cards.[@bib0005]

There were 19,035 patients with CAD (13,619 in EHR practices), 9373 patients with HF (8923 in EHR practices), and 1127 patients with AF (431 in EHR practices). Of the 17 practices, only 2 had fully-integrated and operational EHRs. The mean age of the study population was 51.0 ± 17.6 years, and 67.1% were men. The mean number of encounters per patient were 2.7, with more encounters per patient in non-EHR practices compared with EHR practices (4.4 vs. 2.1). Documentation of co-morbidity burden in patients with CAD was lower among practices with EHR---hypertension (49.8% vs. 52.1%, p = 0.003), diabetes (34.9% vs. 38.3%, p \< 0.001), and hyperlipidemia (0.2 vs. 3.9%, p \< 0.001). On the contrary, documentation of medication prescription was higher in CAD patients seen at practices with EHR---aspirin (63.2% vs. 17.8%, p \< 0.001), clopidogrel (41.7% vs. 27.4%, p \< 0.001), beta-blockers (61.4% vs. 9.8%, p \< 0.001), and ACE-i or ARBs (53.9% vs. 16.4%, p \< 0.001). Similarly, documentation of receipt of beta-blockers (43.8% vs. 10.7%, p \< 0.001), ACE-i or ARBs (40.8% vs. 16.1%, p \< 0.001), and beta-blockers + ACE-i or ARBs (36.4% vs. 3.6%, p \< 0.001) was also significantly higher in patients with HF seen at practices with EHR. Among patients with AF, documentation of warfarin use was significantly higher among EHR practices --- 42.5% vs. 26.1%, p \< 0.001 ([Table 1](#tbl0005){ref-type="table"}). In adjusted logistic regression analyses, presence of EHR was independently associated with better documentation of medication prescription across the spectrum of cardiovascular diseases --- CAD (aspirin, OR 11.62 \[95% CI 10.6--12.8\]; clopidogrel, OR 2.05 \[95% CI 1.9--2.2\]; beta-blockers, OR 31.95 \[95% CI 28.0--36.4\]; and ACE-i or ARBs, OR 8.62 \[95% CI 7.8--9.5\]), HF (beta-blockers, OR 78.60 \[95% CI 48.9--126.2\]; ACE-i or ARBs, OR 12.90 \[95% CI 9.3--18\]; and beta-blockers + ACE-i or ARBs, OR 649.2 \[95% CI 305--1382.1\]), and AF (warfarin, OR 1.84 \[95% CI 1.5--2.2\]).Table 1![](fx1.gif)

Our results indicate that the documentation of receipt of GDMT in CAD, HF, and AF was significantly higher in practices with EHR in India compared with sites without EHR. Study limitations include lack of data on medication contraindications that along with variable documentation practices in India may have impacted GDMT prescription. Our results cannot be entirely explained by better documentation because of EHR use, as baseline co-morbidities were more frequently documented in practices with no EHR.

Our findings have implications in future health care policy-making in India with regard to widespread adoption of EHRs in primary and advanced specialty care OPDs in both public and private health care settings.
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